Drug profile · INN
capsaicin
QUTENZA
capsaicin (QUTENZA) is a vanilloid receptor opener. Route of administration: topical. Current US regulatory status: approved.
Drug details — capsaicin
- US status
- approved
- Class
- Nervous system (N01)
- Route
- TOPICAL
- Patents
- 5
- Programs
- 5
- Data quality
- 0.84
Quick answer
capsaicin (QUTENZA) is a vanilloid receptor opener. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Vanilloid receptor opener
Primary target: Transient receptor potential cation channel subfamily V member 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 7097991
Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
granted -
US 6790629
Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
expired -
US 6335180
Nucleic acid sequences encoding capsaicin receptor and uses thereof
expired -
US 6248788
Therapeutic method with capsaicin and capasicin analogs
expired -
US 6239180
Transdermal therapeutic device and method with capsaicin and capsaicin analogs
expired
Frequently asked questions
What is capsaicin?
capsaicin (QUTENZA) is a vanilloid receptor opener. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for capsaicin?
QUTENZA is a marketed brand name for capsaicin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of capsaicin?
capsaicin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.